Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6408 posts found.

Parents warned as child respiratory illness on the rise this summer

July 23, 2021 Medical Communications

Parents are being warned to be on the lookout for signs of a common childhood respiratory illness, RSV, as cases …
News
cdc-un8tv9pw2ik-unsplash_1

Two shots of Pfizer or AstraZeneca vaccine are effective against Delta variant

July 22, 2021 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

A new study has shown that two shots of either Pfizer or AstraZeneca’s COVID-19 vaccine are nearly as effective against …
News
roche__tree

Roche discussing potential Alzheimer’s treatment with FDA

July 22, 2021 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Roche is discussing its potential treatment, gantenerumab, for Alzheimer’s disease with the FDA as clinical trials proceed. Chief Executive Severin …
News

NICE approves treatment for rare bile duct cancer

July 22, 2021 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

NICE has approved Pemigatinib (Pemazyre) as first treatment for people with a rare form of bile duct cancer (cholangiocarcinoma). Pemigatinib, …
News

J&J ‘one shot’ vaccine ineffective against Delta variant, study finds

July 21, 2021 Medical Communications, Research and Development

A new study posted online on Tuesday, has found that Johnson & Johnson’s COVID-19 vaccine is much less effective against …
News

Pfizer to pay $345 million in EpiPen lawsuit

July 16, 2021 Medical Communications Mylan, Pfizer, epipen

Pfizer has reached a $345 million settlement over consumer claims they overpaid for EpiPens as a result of unfair, anticompetitive …
News

Drugmakers fined a record £260 million after 10,000% drug price increase

July 16, 2021 Medical Communications UK

The UK’s competition authority has issued its largest ever fine of more than £260 million ($360 million) to several pharma …
News

Younger adults with COVID still at risk of serious organ damage

July 16, 2021 Medical Communications

Young adults admitted to hospital with COVID-19 are almost as likely to experience complications as those over 50, a study …
News

EMA validates HUTCHMED MAA for neuroendocrine tumour drug

July 16, 2021 Medical Communications EU, oncology

China-based biotech HUTCHMED has announced that the EMA has validated and accepted the Marketing Authorisation Application (MAA) for surufatinib, for …
News

NICE rejects gene therapy for children with neurodegenerative disorder

July 9, 2021 Medical Communications

NICE does not recommend gene therapy OTL-200 (also called Libmeldy and made by Orchard Therapeutics) for treating children with the …
News

FDA narrows guidance on controversial Alzheimer’s drug

July 9, 2021 Medical Communications

A month after the approval of Biogen’s controversial new Alzheimer’s drug, Aduhelm, the FDA has narrowed its guidance on who …
News
biogen_austria_238

Global genetic exome sequence analysis collaboration announced

July 9, 2021 Medical Communications

AbbVie, Pfizer, and Biogen have announced the launch of the world’s largest browsable resource linking rare protein-coding genetic variants to …
News

Tech successful in harvesting cancer cells in brain metastases patients

July 9, 2021 Medical Communications

The University Medical Centre Hamburg-Eppendorf has published results of new work undertaken in patients with brain metastasis using ANGLE’s cell …
News

Children “extremely low risk” from COVID study finds

July 9, 2021 Medical Communications COVID-19, Vaccine

The overall risk of children becoming severely ill or dying from COVID-19 is extremely low, scientists from University College London, …
News
az

AstraZeneca MPO inhibitor shows promise for heart failure patients

July 2, 2021 Medical Communications

Results released from AstraZeneca’s Phase IIa SATELLITE trial demonstrated that AZD4831, a myeloperoxidase (MPO) inhibitor, achieved pre-specified target engagement in …
News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026